[18F]AV45(Aβ) and [18F]AV1451(Tau)PET/CT in the Diagnosis of Early Pathological Changes of Alzheimer's Disease

Launched by SICHUAN PROVINCIAL PEOPLE'S HOSPITAL · Feb 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying new imaging techniques to help detect early signs of Alzheimer's disease. Researchers are using special brain scans called PET/CT with two different markers, [18F]AV45 and [18F]AV1451, to look for changes in the brain that could indicate the disease. The goal is to find a more objective way to diagnose Alzheimer's disease early, which can lead to better treatment options and management.

To participate in this study, individuals should be between the ages of 65 and 74 and meet specific criteria for mild cognitive impairment (MCI) or early-stage Alzheimer's disease. This means they may have noticeable memory problems but are not yet experiencing full-blown dementia. Participants will undergo brain scans and cognitive tests. It’s important to note that individuals with certain other neurological or systemic conditions may not be eligible for this trial. This research could provide valuable insights into how Alzheimer's develops and improve diagnostic methods in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Meet the MCI diagnostic criteria of Peterson in 2004;
• • The clinicaldementiarating Scale (CDR) score was 0.5;
• • Prominent memory loss may also be accompanied by impairment of other cognitive domains;
• • Insidious onset and slow progression;
• • Not at the level of dementia.
• AD entry criteria:
• • Meet the criteria for diagnosing dementia as described in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-R), Use the diagnostic criteria for AD from the National Institute of Neurology, Speech and Communication Disorders and Stroke - Alzheimer's Disease and Related Disorders (NINCDS-ADRDA) or the National Institute on Aging and Alzheimer's Disease Association (NIA-AA).
• • Clinical Dementia Rating Scale score was 1 point.
• Exclusion Criteria:
• • Patients with a history of stroke and focal neurological signs, and imaging findings consistent with small cerebral vascular disease (Fazekas score ≥2);
• • The presence of other neurological disorders that can cause brain dysfunction (e.g., depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, Normal facial pressure hydrocephalus);
• • The presence of other systemic diseases that can cause cognitive impairment (such as liver insufficiency, renal insufficiency, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.);
• • There is mental and neurological retardation.
• • There are other diseases that are known to cause cognitive impairment.